Lexicon Pharmaceuticals | LXRX - Operating Expenses


Lexicon Pharmaceuticals reported $20.27M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Abbott USD 9.31B 104M Mar/2026
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Illumina USD 852M 51M Mar/2026
Insmed USD 506.24M 7.31M Mar/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 17.44B 1.53B Mar/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
MacroGenics USD 21.2M 32.13M Mar/2026
MannKind USD 110.9M 8.74M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Moderna USD 1.78B 242M Mar/2026
Novartis USD 9.29B 507M Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Thermo Fisher Scientific USD 9.09B 821M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025